ÂÜÀòÂÒÂ×

Dr. Alan Lewis is the founding Director of Targazyme and was a long Ome board member of Biomarin. Dr. Lewis was the President, CEO, and Chairman of Ambit BioSciences, and previously President and CEO of the Juvenile Diabetes Research FoundaOon and President, CEO, and Director of Novocell, Inc. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal PharmaceuOcals before its acquisition by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases, aper which he served as President of the Signal Research Division at Celgene. Before joining Signal, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin PharmaceuOcal, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.